Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

This weight-loss drug, designed for obese patients, significantly reduces breathing disruptions and offers a new treatment ...

Now, new research suggests Eli Lilly’s weight loss drug Zepbound (tirzepetide) may also support those with obstructive sleep apnea by increasing airflow and improving sleep quality. Since sleep ...

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea. Eli Lilly said the FDA approved Zepbound for moderate-to-severe ...

It's marketed under the brand name Mounjaro in the U.S. for treating type 2 diabetes, and under the brand name Zepbound as ... in treating obstructive sleep apnea. It's also evaluating the drug ...

including snoring and obstructive sleep apnea. Obstructive sleep apnea is when a person stops breathing five or more times per hour. When breathing stops, it can lower oxygen levels, affecting the ...

Sleep disordered breathing is a range of conditions that cause abnormal breathing during sleep including snoring and obstructive sleep apnea. Obstructive sleep apnea is when a person stops ...

Sleep apnea, a widespread health issue, causes breathing interruptions during sleep, leading to oxygen deprivation and various health problems. It manifests in obstructive, central, and mixed forms.